PAXLOVID safety under the microscope: 3,300 patients studied
NCT ID NCT05263908
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study from Pfizer looked at the safety and effects of the COVID-19 medicine PAXLOVID in over 3,300 people aged 12 and older. All participants took PAXLOVID twice a day for five days and were monitored for 28 days. The main goal was to track any side effects, including serious ones. Because this was an observational study, it helps us understand how the drug works in everyday use, but it does not compare PAXLOVID to a placebo or other treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nirmatrelvir / ritonavir (PAXLOVID)
What this could lead to
If successful, this study could confirm that PAXLOVID is safe and effective for treating COVID-19 in a real-world setting.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It also only looks at short-term safety over 28 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer Local County
Tokyo, 1518589, Japan